1. Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. (August 2020) Authors: Brueckl, Wolfgang M; Reck, Martin; Rittmeyer, Achim; Kollmeier, Jens; Wesseler, Claas; Wiest, Gunther H; Christopoulos, Petros; Tufman, Amanda; Hoffknecht, Petra; Ulm, Bernhard; Reich, Fabian; Ficker, Joachim H; Laack, Eckart Journal: Clinical medicine insights. Oncology Issue: Volume 14(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗